• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗晚期帕金森病伴有严重症状波动和异动症患者的策略。

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.

作者信息

Stocchi F, Nordera G, Marsden C D

机构信息

Mediterranean Institute of Neuroscience, Pozzilli, Italy.

出版信息

Clin Neuropharmacol. 1997 Apr;20(2):95-115. doi: 10.1097/00002826-199704000-00001.

DOI:10.1097/00002826-199704000-00001
PMID:9099462
Abstract

Patients with advanced Parkinson's disease often develop severe fluctuations and dyskinesias while receiving long-term levodopa therapy. These complications can prove increasingly difficult to control. Here we review our strategies for coping with such problems. These include establishing the best rational schedule of levodopa treatment, optimizing levodopa absorption, the use of oral dopaminergic agonists, and the use of subcutaneous injections or infusions of apomorphine or lisuride. The problems of severe dyskinesias, sleep disturbances, psychotoxicity, and urinary difficulties also are considered. Finally, the role of new surgical procedures to treat Parkinson's disease is reviewed.

摘要

晚期帕金森病患者在接受长期左旋多巴治疗时常常会出现严重的症状波动和异动症。这些并发症会越来越难以控制。在此,我们回顾应对此类问题的策略。这些策略包括制定最佳的左旋多巴合理治疗方案、优化左旋多巴吸收、使用口服多巴胺能激动剂,以及皮下注射或输注阿扑吗啡或利苏瑞肽。还会考虑严重异动症、睡眠障碍、精神毒性和排尿困难等问题。最后,会回顾治疗帕金森病的新手术方法的作用。

相似文献

1
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.治疗晚期帕金森病伴有严重症状波动和异动症患者的策略。
Clin Neuropharmacol. 1997 Apr;20(2):95-115. doi: 10.1097/00002826-199704000-00001.
2
Prevention and treatment of motor fluctuations.运动波动的预防与治疗。
Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S73-81. doi: 10.1016/s1353-8020(03)00021-x.
3
Treatment of levodopa-induced motor complications.左旋多巴诱发的运动并发症的治疗。
Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052.
4
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.帕金森病立体定向神经外科手术中递增剂量阿扑吗啡的效果:临床评分与苍白球内侧部活动。简短通讯
J Neural Transm (Vienna). 1997;104(8-9):895-904. doi: 10.1007/BF01285557.
5
[Prevention and treatment of fluctuations in patients with Parkinson's disease].帕金森病患者病情波动的防治
Praxis (Bern 1994). 2006 Dec 20;95(51-52):2013-8. doi: 10.1024/1661-8157.95.51.2013.
6
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.持续皮下注射阿扑吗啡用于帕金森病左旋多巴诱导的剂末异动症的长期治疗
J Neurol Neurosurg Psychiatry. 1998 May;64(5):573-6. doi: 10.1136/jnnp.64.5.573.
7
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.皮下注射阿扑吗啡:关于其在帕金森病中应用的循证综述
Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.
8
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.药物与药物递送在 PD 中的应用:用普拉克索控释片优化症状控制。
Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x.
9
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.帕金森病患者中,利苏瑞得静脉输注与口服左旋多巴的前瞻性随机试验。
Brain. 2002 Sep;125(Pt 9):2058-66. doi: 10.1093/brain/awf214.
10
[Limits of conventional oral and transdermal medication in Parkinson's disease].[帕金森病中传统口服及透皮给药的局限性]
Rev Neurol. 2012;55 Suppl 1:S3-6.

引用本文的文献

1
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.靶向β-arrestins 治疗精神神经疾病。
CNS Drugs. 2021 Mar;35(3):253-264. doi: 10.1007/s40263-021-00796-y. Epub 2021 Mar 2.
2
G protein-coupled receptor kinases as regulators of dopamine receptor functions.G蛋白偶联受体激酶作为多巴胺受体功能的调节因子。
Pharmacol Res. 2016 Sep;111:1-16. doi: 10.1016/j.phrs.2016.05.010. Epub 2016 May 10.
3
Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
GRK6的过表达可挽救偏侧帕金森病大鼠多巴胺耗竭纹状体中左旋多巴诱导的信号异常。
Exp Neurol. 2015 Apr;266:42-54. doi: 10.1016/j.expneurol.2015.02.008. Epub 2015 Feb 14.
4
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.变构调节 III 组 mGlu4 受体为帕金森病 6-羟多巴胺大鼠模型提供了功能性神经保护。
Br J Pharmacol. 2012 Aug;166(8):2317-30. doi: 10.1111/j.1476-5381.2012.01943.x.
5
The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.GRK6 在帕金森病动物模型和 L-DOPA 治疗中的作用。
Sci Rep. 2012;2:301. doi: 10.1038/srep00301. Epub 2012 Mar 5.
6
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.黑质内群 III 代谢型谷氨酸受体激活对帕金森病啮齿动物模型的症状和神经保护作用。
Br J Pharmacol. 2010 Aug;160(7):1741-53. doi: 10.1111/j.1476-5381.2010.00820.x.
7
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.纹状体 5-羟色胺和 L-氨基酸脱羧酶在半帕金森病大鼠模型中左旋多巴诱导的运动障碍中的作用。
Cell Mol Neurobiol. 2010 Aug;30(6):817-25. doi: 10.1007/s10571-010-9509-9. Epub 2010 Mar 16.
8
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.纹状体对5-羟色胺1A受体刺激在左旋多巴治疗的偏侧帕金森病大鼠中所产生效应的作用。
J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.
9
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.外源性皮质酮可减轻半帕金森病大鼠中左旋多巴诱导的运动障碍:白细胞介素-1β的作用
Neuroscience. 2008 Sep 22;156(1):30-41. doi: 10.1016/j.neuroscience.2008.07.016. Epub 2008 Jul 12.
10
Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.多巴胺耗竭的大鼠基底神经节中GRK亚型的表达和亚细胞分布改变,左旋多巴治疗不能使其恢复正常。
J Neurochem. 2008 Mar;104(6):1622-36. doi: 10.1111/j.1471-4159.2007.05104.x. Epub 2007 Nov 7.